# Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

> **NCT07145255** · PHASE1,PHASE2 · RECRUITING · sponsor: **MBrace Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Prostate Cancer Castration-resistant Prostate Cancer
- Breast Cancer
- Colo-rectal Cancer
- Lung Cancer (Non-Small Cell)
- Pancreas Cancer, Duct Cell Adenocarcinoma

## Interventions

- **DRUG:** ADC

## Key facts

- **NCT ID:** NCT07145255
- **Lead sponsor:** MBrace Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-03
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145255, "Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07145255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*